Rapport Therapeutics CEO Abraham Ceesay reports sale of common shares worth $64,447.578

RAPP•2026-10-23

CEO Abraham Ceesay sold 2,210 Rapport Therapeutics common shares on Oct. 21, 2026, at $29.1618 per share, for a total of $64,447.578.

1. Share sale

Following the sale, Ceesay directly owned 450,035 common shares. He also held 81,729 shares through the Ceesay Family Irrevocable Trust and 20,729 through the Dorothy Ceesay Irrevocable Trust.

Sources

Rapport Therapeutics CEO Abraham Ceesay reports sale of common shares worth $64,447.578

Sec

Rapport Therapeutics CEO Abraham Ceesay reports sale of common shares worth $64,447.578

1. Share sale

Related News

Air Products and Chemicals announces dividend of R$ 0.257024813 per unit

Old Dominion Freight Line announces dividend of R$ 0.0494095740 per BDR

Unusual Machines completes acquisition of Upgrade Energy

Sources

Rapport Therapeutics CEO Abraham Ceesay reports sale of common shares worth $64,447.578

City Holding director Robert D. Fisher reports acquisition of $23,451.45 in common shares

PNC completes $1.5 billion senior debt offering